Keyuan Pharmaceutical has released its 2026 half-year performance forecast, expecting net profit for the first half to be between 60 million and 65 million yuan, a year-on-year increase of 40.57% to 52.29%. The company stepped up efforts to develop the formulation market and introduced new products, leading to higher sales of new products. At the same time, it continued to optimize internal refined operations management, steadily advanced cost reduction and efficiency improvement, and raised production efficiency, resulting in an increase in the gross margin of formulation products.
Shandong Keyuan Pharmaceutical Co. Ltd. ACompany expects net profit to rise 40.57%-52.29% YoY, driven by new product sales and cost efficiency.